Adult Dosing
Obsessive-compulsive disorder
- Immediate release
- Start 50 mg PO qhs
- Increase 50 mg q4-7 days until maximum benefit is achieved
- MAX: 300 mg/day
- Give total daily doses
100 mg in two divided doses - Taper dose gradually to discontinue
- Extended release
- Start 100 mg PO qhs
- Increase 50 mg/day qwk
- Max: 300 mg/day
Social anxiety disorder
- Start 100 mg PO qhs
- Increase 50 mg/day qwk
- Max: 300 mg/day
Pediatric Dosing
Obsessive-compulsive disorder
- 8-11 yrs
- Start 25 mg PO qhs
- Increase 25 mg q4-7 days until maximum benefit is achieved
- MAX: 200 mg/day
- Usual range: 50-200 mg/day divided qd-bid
- Give total daily doses 50 mg in two divided doses
- 12-17 yrs
- Start 25 mg PO qhs
- Increase 25 mg q4-7 days until maximum benefit is achieved
- MAX: 300 mg/day
- Usual range: 50-200 mg/day divided qd-bid
- Give total daily doses 50 mg in two divided doses
[Outline]
- Increased suicidal tendencies and behavioural changes have been reported in children, adolescents, and young adults, especially during first months of treatment. Suicidality risk was not increased in patients > 24 years and risk decreased in patients > 65 years. Carefully weigh the risks and benefits before starting treatment. Monitor patients closely for clinical worsening, suicidal tendencies and unusual changes in behavior; particularly early in therapy or after increases in dose [US Black Box Warning]
- Gradually taper when discontinuing to avoid withdrawal symptoms
- Observe patients for worsening depression or the emergence of suicidality, anxiety, agitation, panic attacks, particularly early in therapy or after increases in dose
- Monitor growth parameters in pediatric patients
- It may interfere with cognitive performance; caution patients against engaging in activities requiring mental alertness eg operating machinery and driving
- Infants exposed to fluvoxamine in late pregnancy may be at risk of persistent pulmonary hypertension of the newborn
Cautions: Use cautiously in
- Hepatic impairment
- Hx of seizure disorder
- Hx of cardiac disease
- Hx of bleeding disorders
- Risk factors for bleeding
- Hx of manic disorder
- Diabetes mellitus
- Dehydration
- Volume depletion
- Concurrent diuretics
- Pregnancy > 20 wks gestation
- Lactation (safety not established)
- Geriatric population
- Smoking habit changes
Pregnancy Category:C
Breastfeeding: Probably safe. Limited information indicates that doses up to 300 mg/day produce low levels in breastmilk and would not be expected to cause any adverse effects in breastfed infants, especially if the infant is older than 2 months. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 2 February 2011).
US Trade Name(s)
US Availability
fluvoxamine (generic)
- TABS: 25, 50, 100 mg
- ECAPS: 100, 150 mg
Luvox
Luvox CR
Canadian Trade Name(s)
Canadian Availability
fluvoxamine (generic)
Luvox
UK Trade Name(s)
UK Availability
fluvoxamine (generic)
Faverin
Australian Trade Name(s)
Australian Availability
fluvoxamine (generic)
Faverin, Luvox, Movox, Voxam
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- FluvoxaMINE Maleate 100 MG TABS [Bottle] (ANI PHARMACEUTICALS)
50 mg = $116
100 mg = $215.95 - Luvox CR 100 MG CP24 [Bottle] (JAZZ PHARMACEUTICALS)
30 mg = $255
90 mg = $749.98 - Luvox CR 150 MG CP24 [Bottle] (JAZZ PHARMACEUTICALS)
30 mg = $280
90 mg = $809.95
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
